Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Cangzhou edge Chengdu for first win of seasonCicadas are so noisy in South Carolina that residents are calling the policeStrawberry Music Festival to be held at Beijing Expo ParkUS returns 38 pieces of cultural objects to ChinaHuilongwo: a chic and historical block in XuzhouChina defender Zhang backtracks on retirement claimChinese mainland, HK resume normal travel after three yearsYanqing's top destinations to travel around in autumnAffluent Americans are driving US economy and likely delaying need for Fed rate cutsReading campaign launched among college students in China
3.2484s , 6496.234375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,International Intrigue news portal